Three-year data have confirmed the effectiveness of a strategy that eliminated all third-generation cephalosporins from a formulary as a means to control the emergence of vancomycin-resistant enterococcus (VRE).
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.